Marie Luise Hütter‐Krönke

Author

Novartis Institutes for BioMedical Research ORCID

Also Known As

L-M Hütter-Krönke, M.-L. Hutter-Kronke, M.-L. Hütter-Krönke, M.L. Hütter-Krönke, Marie L. Hütter-Krönke, Marie Luise Hutter-Kronke, Marie Luise Hütter-Krönke, Marie Luise Hütter‐Krönke

Publications

594

Citations

H-Index

Concepts

All Affiliations

Novartis Institutes for BioMedical Research National Taiwan University Hospital Novartis (Switzerland)University Hospital Ulm Princess Margaret Cancer Centre

About

Marie Luise Hütter‐Krönke is an author at Novartis Institutes for BioMedical Research specializing in cancer therapeutics, health sciences, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	1	1	15
2	Medicine	1	1	15
3	Pathology	1	1	15
4	Pharmacology	1	1	15
5	Cancer Therapeutics	1	1	15

Marie Luise Hütter‐Krönke

Publications

502

Citations

H-Index

Page 1

	Year	Citations
PD-1 Blockade in Anaplastic Thyroid Carcinoma Jaume Capdevila, Lori J. Wirth, Thomas Ernst, Journal of Clinical Oncology	2020	335
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study Albiruni R. Abdul Razak, Sebastian Bauer, Cristina Suárez, Clinical Cancer Research	2021	61
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors Todd M. Bauer, Armando Santoro, Chia‐Chi Lin, Journal for ImmunoTherapy of Cancer	2023	33
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study David J. Kuter, Waleed Ghanima, Nichola Cooper, Blood	2025	27
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy Marie Luise Hütter‐Krönke, Axel Benner, Konstanze Döhner, Haematologica	2016	21
Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma Albiruni Abdul Razak, Sebastian Bauer, Jean‐Yves Blay, Cancer Research Abstract Ct009Malignant DiseaseMedicinePharmacologyPathology	2018	15
Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation Marie Luise Hütter‐Krönke, Adela Neagoie, Igor Wolfgang Blau, Frontiers in Immunology	2023	10

Page 1